Tissue Regenix Group PLC Additional Director Disclosures (3465B)
February 10 2022 - 12:23PM
UK Regulatory
TIDMTRX
RNS Number : 3465B
Tissue Regenix Group PLC
10 February 2022
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
Additional Director Disclosures
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, announces the following additional disclosures under
Schedule 2(g) of the AIM Rules for Companies relating to Brian
Phillips, Non-Executive Director. These are in addition to those
details already announced on 5 January 2021.
Mr Phillips' career in private equity resulted in him holding a
number of non-executive directorship positions in respect of his
firm's investee companies, including the following: Diamond Group
Holdings Public Limited Company to which a receiver was appointed
in 1992; Mr Phillips was a director of group companies, The Allen
Partnership Limited and Public House Holdings Limited, when an
administration order was made on both companies in October 1992;
Cannock Group Limited went into voluntary creditors' liquidation in
December 1998 while Mr Phillips was a director; and a receiver was
appointed in respect of the administration of Alma Holdings Limited
in February 1992 while Mr Phillips was a director.
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Alex Price
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, foot & ankle, dental, and sports medicine surgical
procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RDNUROVRUOUUAAR
(END) Dow Jones Newswires
February 10, 2022 10:44 ET (15:44 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024